title: Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.
abstract: No previous study has investigated how the vaso-constrictive peptide Ang II impacts insulin action in isolated mammalian skeletal muscle. We investigated the molecular actions of Ang II on insulin signalling and glucose transport in skeletal muscle from lean Zucker rats. Soleus strips were incubated with insulin (5 mU/ml) and/or Ang II (500 nM) for 2 hours. Ang II caused significant (p < 0.05) inhibition of insulin-stimulated glucose transport (39%) and decreased phosphorylation of Akt Ser(473) (37%) and glycogen synthase kinase-3beta Ser(9) (42%) without affecting phosphorylation of IRS-1 Ser(307) or p38 MAPK. We used the superoxide dismutase mimetic, tempol (1 mM), to determine if reactive oxygen species (ROS) contribute to Ang II-mediated insulin resistance. Tempol partially reversed (42%) Ang II-induced inhibition of insulin-stimulated glucose transport. These results indicate that Ang II inhibits distal insulin signalling and insulin-stimulated glucose transport in isolated mammalian skeletal muscle, and that this effect is partially mediated by ROS.
authors.affiliation: Muscle Metabolism Laboratory, Department of Physiology and Arizona Diabetes Program, University of Arizona College of Medicine, Tucson, AZ 85721-0093, USA.
authors.forename: Maggie K
authors.initials: MK
authors.lastname: Diamond-Stanic
authors.forename: Erik J
authors.initials: EJ
authors.lastname: Henriksen
mesh_terms: D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001692:Biological Transport; D005260:Female; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism* / Q000494:pharmacology; D020930:MAP Kinase Kinase Kinases; D008322:Mammals / Q000378:metabolism; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D011924:Rats, Zucker; D017382:Reactive Oxygen Species / Q000378:metabolism* / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism / Q000494:pharmacology
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D011518:Proto-Oncogene Proteins; D017382:Reactive Oxygen Species; D000804:Angiotensin II; D051057:Proto-Oncogene Proteins c-akt; D048051:p38 Mitogen-Activated Protein Kinases; D020930:MAP Kinase Kinase Kinases; C069937:MAP3K8 protein, human; D005947:Glucose
references.citation: N Engl J Med. 2006 Oct 12;355(15):1551-62
references.pmid: 16980380
references.citation: Am J Physiol. 1999 Nov;277(5):E920-6
references.pmid: 10567021
references.citation: Free Radic Biol Med. 2009 Sep 1;47(5):593-9
references.pmid: 19500665
references.citation: J Biol Chem. 2005 Feb 11;280(6):4422-8
references.pmid: 15574412
references.citation: Hypertension. 2002 Dec;40(6):872-9
references.pmid: 12468572
references.citation: Eur J Pharmacol. 2005 Sep 27;520(1-3):179-87
references.pmid: 16139267
references.citation: N Engl J Med. 2000 Mar 30;342(13):905-12
references.pmid: 10738048
references.citation: Metabolism. 2007 Jul;56(7):931-8
references.pmid: 17570255
references.citation: Am J Physiol. 1996 Jun;270(6 Pt 1):E919-29
references.pmid: 8764174
references.citation: Regul Pept. 2000 Jul 28;91(1-3):21-7
references.pmid: 10967199
references.citation: N Engl J Med. 2000 Jan 20;342(3):145-53
references.pmid: 10639539
references.citation: Hypertension. 1996 Apr;27(4):854-8
references.pmid: 8613260
references.citation: Hypertension. 2007 Aug;50(2):384-91
references.pmid: 17533199
references.citation: Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E353-9
references.pmid: 15494608
references.citation: Free Radic Biol Med. 2009 Nov 15;47(10):1486-93
references.pmid: 19703555
references.citation: Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1074-81
references.pmid: 15657091
references.citation: Lancet. 1999 Feb 20;353(9153):611-6
references.pmid: 10030325
references.citation: Hypertension. 2001 Oct;38(4):884-90
references.pmid: 11641303
references.citation: JAMA. 2002 Sep 25;288(12):1491-8
references.pmid: 12243636
references.citation: J Appl Physiol (1985). 1994 May;76(5):1862-7
references.pmid: 8063642
references.citation: Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E615-21
references.pmid: 18089761
references.citation: J Clin Invest. 1997 Nov 1;100(9):2158-69
references.pmid: 9410892
references.citation: Metabolism. 2005 Dec;54(12):1659-68
references.pmid: 16311101
references.citation: Metabolism. 1995 Feb;44(2):267-72
references.pmid: 7869926
references.citation: J Biol Chem. 2006 Nov 17;281(46):35137-46
references.pmid: 16982630
references.citation: Free Radic Biol Med. 2006 Sep 1;41(5):818-24
references.pmid: 16895802